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ABSTRACT
This study reviews extensive genetic analysis in advanced non-small cell 
lung cancer (NSCLC) patients in order to: describe how targetable mutation genes 
interrelate with the genes identified as variants of unknown significance; assess the 
percentage of patients with a potentially targetable genetic alterations; evaluate the 
percentage of patients who had concurrent alterations, previously considered to be 
mutually exclusive; and characterize the molecular subset of KRAS.
Thoracic Oncology Research Program Databases at the University of Chicago 
provided patient demographics, pathology, and results of genetic testing. 364 patients 
including 289 adenocarcinoma underwent genotype testing by various platforms such 
as FoundationOne, Caris Molecular Intelligence, and Response Genetics Inc. For the 
entire adenocarcinoma cohort, 25% of patients were African Americans; 90% of 
KRAS mutations were detected in smokers, including current and former smokers; 
46% of EGFR and 61% of ALK alterations were detected in never smokers. 99.4% of 
patients, whose samples were analyzed by next-generation sequencing (NGS), had 
genetic alterations identified with an average of 10.8 alterations/tumor throughout 
different tumor subtypes. However, mutations were not mutually exclusive.
NGS in this study identified potentially targetable genetic alterations in the 
majority of patients tested, detected concurrent alterations and provided information 




Personalized medicine using genotyping to inform 
clinical decisions has become standard of care for non-
small cell lung cancer (NSCLC) [1, 2]. Advances in 
biomarker-driven therapy have markedly improved 
outcomes for patients with tumor specific molecular 
abnormalities. Although most national and international 
guidelines currently recommend testing for EGFR 
mutations and ALK gene rearrangements [3–5], it is 
becoming increasingly clear that more extensive analysis 
of a tumor’s genetic profile is critical to identifying 
mutations or gene fusions sensitive to already approved 
therapies but not detected by hotspot testing methods 
[6]. Next-generation sequencing (NGS) identifies 
genetic alterations that confer sensitivity to approved and 
investigational-targeted therapies in patients suffering 
from a variety of advanced cancers. A previous study 
showed that a targeted NGS assay identified potentially 
targetable genetic alterations in 83% of tumors, with 21% 
of these patients receiving genotype-directed therapy [7]. 
In that particular study, however, only 7% of patients 
had lung cancer. High-sensitivity genomic profiling can 
also reveal potential new pathways to biomarker-driven 
therapies. In a study of patients with small cell lung 
cancer who had relapsed after primary chemotherapy, 
NGS detected at least one targetable alteration with the 
potential to personalize further therapy in more than 50% 
of cases [8].
In view of the immediate clinical implications 
offered by comprehensive molecular testing, we 
investigated NSCLC patients’ genomic profile results 
of NGS at the University of Chicago for therapeutic 
purposes. In the past five years, we have collected more 
than 300 patients’ genomic testing and therapeutic results 
in the University of Chicago Thoracic Oncology database. 
In this study, we specifically aim to review the results 
of extensive genetic analysis in patients with NSCLC, 
specifically adenocarcinoma (AD) from the database. We 
describe how targetable mutation genes correlate with 
the genes identified as variants of unknown significance. 
We assessed the percentage of patients with a potentially 
targetable genetic alteration. We also evaluated the 
percentage of patients who had concurrent alterations, 
previously considered to be mutually exclusive. In 
addition, we characterize the molecular subset of KRAS, 
one of the most commonly observed genetic mutations in 
NSCLC AD, for which clinical trials with investigational 
agents are being conducted [9].
RESULTS
Next generation sequencing
One hundred and sixty patient tumor samples 
were sequenced by FoundationOne from Foundation 
Medicine (FM) NGS assay over the study period. Table 1 
summarizes the demographic characteristics, histology, 
and molecular markers from specimens analyzed by 
sending the specimens to Foundation Medicine. African 
Americans comprised 26% of the study population. 
Twenty two percent of patients were never smokers. The 
majority (75%) of patients had adenocarcinoma.
Genetic alterations
The vast majority (99.4%) of patients analyzed by 
NGS had genetic alterations identified with an average 
of 10.8 alterations/tumor. Targetable gene alterations 
such as EGFR, KRAS, ALK, ROS1, RAF1, RET, ERBB2, 
PIK3CA, MET, FGF, and potential targetable gene CBL 
were identified throughout tumor subtypes (Table 1). 
Due to the majority (75%) of tumor samples are AD, we 
focused our study in only AD populations. The spectrum 
of potentially targetable genetic alterations including 
mutations, amplifications, homozygous deletions, and 
fusions are summarized in Figure 1. Genetic alterations 
were detected across a wide range of functionally 
relevant pathways (Fig.1). The most common alterations 
involved the receptor tyrosine kinase/growth factors 
(RTK/GFs) genes including EGFR, ALK, MET, RET 
and ROS1. Alterations in the mitogen-activated protein 
kinase (MAPK)/RAS and phosphatidylinositol 3-kinase 
(PI3K)/mTOR pathways were identified in a large 
proportion of samples with 56.7% (68/120) and 30% 
(36/120) respectively. Cell cycle-associated genes were 
dysregulated pathways with mutations, amplifications, 
or deletions present in 25% (30/120) of tumors. KRAS 
mutation was found in 32.5% of patients with 10% of 
mutations detected in never smokers (Table 1). Figure 2 
summarizes the prevalence of detected alterations in the 
population studied.
Concurrent alterations and variants of unknown 
significance (VUS)
We found that not uncommonly, mutations were not 
exactly mutually exclusive. 36.25% (58/160) of samples 
had multiple gene alterations including gene amplification. 
Figure 3A shows the summary along the ordinate the 
number of additional mutations coexisting with a specific 
genetic defect. For example, in patients with KRAS 
mutations, additional mutations were detected in EGFR 
(n= 5), ALK (n=1), RAF1 (n=1), RET (n=3), ERBB2 (n=1), 
PIK3CA (n=3), MET (n= 3) and CBL (n=2). More detailed 
breakdown of gene and gene alteration correlation of 
KRAS, EGFR, and ALK are illustrated in Figure 3B, 3C, 
and 3D. VUS refer to alterations detected in one of the 
genes included on FoundationOne that have not yet been 
adequately characterized in the scientific literature. These 
variants are reported to potentially be acted upon should 
clinical evidence emerge.
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Table 1: Summary of the demographic characteristics, histology, and molecular markers from specimens analyzed 
by FoundationOne
Total EGFR KRAS ALK ROS1 RAF1 RET ERBB2 PIK3CA MET CBL FGF totals
%(#) %(#) %(#) %(#) %(#) %(#) %(#) %(#) %(#) %(#) %(#) %(#)
N = (160) (34) (44) (11) (1) (3) (16) (5) (19) (11) (10) (54)
Sex
Male 49% (79) 41% (14) 39% (17) 45% (5) 0% (-) 67% (2) 56% (9) 60% (3) 74% (14) 64% (7) 40% (4) 52% (28)
Female 51% (81) 59% (20) 61% (27) 55% (6) 100% (1) 33% (1) 44% (7) 40% (2) 26% (5) 36% (4) 60% (6) 48% (26)
Age
Mean (62.1) (63.1) (64.1) (55.4) (52.1) (64.8) (62.4) (66.2) (66.4) (67.7) (66.3)
Race
White 63% (101) 41% (14) 70% (31) 91% (10) 100% (1) 67% (2) 56% (9) 60% (3) 68% (13) 36% (4) 60% (6) 61% (33)
Black 26% (42) 41% (14) 25% (11) 0% (-) 0% (-) 33% (1) 31% (5) 20% (1) 21% (4) 27% (3) 30% (3) 28% (15)
Asian 6% (10) 18% (6) 2% (1) 0% (-) 0% (-) 0% (-) 13% (2) 20% (1) 11% (2) 18% (2) 10% (1) 11% (6)
Other 2% (3) 0% (-) 2% (1) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 9% (1) 0% (-) 0% (-)
Unknown 2% (3) 0% (-) 0% (-) 9% (1) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 9% (1) 0% (-) 0% (-)
Smoking
Smoker 78% (125) 62% (21) 91% (40) 55% (6) 0% (-) 100% (3) 81% (13) 60% (2) 79% (15) 82% (9) 90% (9) 85% (46)
Never 
Smoker 22% (35) 38% (13) 9% (4) 45% (5) 100% (1) 0% (-) 19% (3) 40% (2) 21% (4) 18% (2) 10% (1) 15% (8)
Histology
AD 75% (120) 82% (28) 89% (39) 82% (9) 100% (1) 67% (2) 81% (13) 100% (5) 63% (12) 55% (6) 80% (8) 76% (41)
SCC 9% (15) 3% (1) 0% (-) 0% (-) 0% (-) 33% (1) 13% (2) 0% (-) 37% (7) 18% (2) 0% (-) 11% (6)
NSCLC, 
NOS 4% (7) 3% (1) 2% (1) 9% (1) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 9% (1) 10% (1) 6% (3)
LCC 3% (4) 9% (3) 5% (2) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 9% (1) 0% (-) 4% (2)
Other 8% (3) 3% (1) 5% (2) 9% (1) 0% (-) 0% (-) 6% (1) 0% (-) 0% (-) 9% (1) 10% (1) 4% (2)
AD: Adenocarcinoma, SCC: Squamous cell carcinoma, LCC: Large cell carcinoma, NOS: Not otherwise specified
Figure 1: Number of adenocarcinoma samples with genetic alteration classified by cell signaling pathway. Genetic alterations 
from NGS reports were classified by cell signaling pathway, such as RAS/MAPK, RTK/GFs, PI3K/mTOR, p53, Wnt pathways, and cell cycling. 
The ordinate indicated number of adenocarcinoma samples with alterations. RTK/GFs: Receptor tyrosine kinase/ Growth factors.
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Figure 2: NSCLC adenocarcinoma patients’ genetic alterations detected by NGS. In all the patient samples tested, 23.3% of 
EGFR, 32.5% of KRAS, 7.5% of ALK, 0.8% of ROS1, 1.7% of RAF1, 10.8% of RET, 4.2% of ERBB2, 10.0% of PIK3CA, 5.0% of MET, 
6.7% of CBL, and 12.5% of BRAF alteration were detected.
Figure 3: Gene and gene alteration correlation. Genetic alteration was detected by NGS. Gene and gene alteration correlation is 
shown in A. A summary of a number of additional mutations (ordinate) coexisting with a specific genetic (abscissa) defect was observed. 
Samples that had B. KRAS, C. EGFR, and D. ALK were further analyzed respectively. The pie charts show the percentage of samples of 
each different gene alteration coexisted. Mutations were not mutually exclusive.
Oncotarget18880www.impactjournals.com/oncotarget
Including FM, Caris Molecular Intelligence 
(CMI), and Response Genetics Inc. (RG) results, the 
prevalence of genetic alterations, patients and tumor 
characteristics for the entire AD dataset (N=289) are 
described in Table 2. African Americans comprised 25% 
of the study population. Adenocarcinoma was the most 
commonly tested tumor subtype of NSCLC and NSCLC-
NOS comprised 13% of the specimens submitted for 
molecular analysis. 90% of KRAS mutations were 
detected in smokers, including current and former 
smokers. 46% of EGFR and 61% of ALK alteration 
were detected in never smokers. Thirteen percent of 
ALK alterations were seen in African Americans (Table 
2). 85.8% (248/289), 85.5% (247/289), and 85.1% 
(246/289) of the patients in the entire cohort were tested 
for EGFR, KRAS, and ALK respectively. 23% (57/248) 
of the EGFR tested samples showed genetic alteration 
(Figure 4A). The details of the genetic alteration have 
been analyzed and are listed in Figure 4. EGFR exon 
19 deletion showed in a majority of the samples. In 
addition, 34% (84/247) of KRAS tested samples showed 
genetic alteration and 40.5% (34/84) of these KRAS 
alteration samples had G12C mutation (Figure 4B). 
9.3% (23/246) of ALK tested samples showed genetic 
alteration and 78.3% (18/23) of these ALK alteration 
samples had EML4-ALK rearrangement (Figure 4C). 
As in this study, mutations were not mutually exclusive. 
Some patients with EGFR or KRAS amplification also 
had other EGFR or KRAS mutations.
DISCUSSION
We report a single institution’s 5-year experience 
of implementing comprehensive genetic testing 
including NGS in patients with advanced NSCLC. 
Genetic alterations were identified by NGS in the vast 
majority of patients with NSCLC, and this analysis 
shows the changing platforms that have occurred over 
the past several years. Currently targetable alterations 
were identified in a significant proportion of NSCLC. 
Our findings highlight the importance of testing not 
only adenocarcinoma, but to broaden the testing to the 
other NSCLC subtypes as is currently recommended by 
guidelines [10]. The variety of genetic alterations reported 
independent of race, age, sex or smoking status is also in 
line with the current recommendations from national and 
international guidelines [10–12].
A prior study showed that the presence of KRAS 
mutation excludes the possibility of EGFR mutation 
or ALK translocation [13]. In fact, some testing 
algorithms suggested to first test for KRAS and if 
negative proceed with EGFR, then ALK [14]. Coexisting 
targetable alterations were indeed not uncommon 
in our patients. Our findings would suggest that we 
should have a more comprehensive approach rather 
than a sequential approach. Given the turnaround time 
of at least 2-3 weeks (and longer if a patient has the 
biopsy while hospitalized due to Medicare/insurance 
rules) and the advanced disease state of this patient 
population, sequential testing (even when only KRAS, 
EGFR and ALK status are analyzed) would delay care. 
Targeted NGS approach has potential value in several 
additional ways. Novel, potentially active therapies 
can be identified, enabling clinical trial enrollment 
for patients without available treatment options. Even 
“negative” results from NGS are useful to direct 
patients toward immunotherapy (anti-PD1, anti-PD-L1) 
trials, further chemotherapy or comfort care. NGS 
allows identifications of VUS, which could become 
valuable in the near future as our understanding of 
prognostic and predictor markers of response continues 
to evolve. Oncogenic fusions, such as those involving 
kinases, continue to be discovered (i.e. KIF5B-RET) 
and may have immediate implications on lung cancer 
management [15].
There are several limitations to this study. 
Results were evaluated in a retrospective fashion. The 
impact of NGS on downstream cost-effectiveness was 
not thoroughly assessed in this analysis. Published 
data suggest, however, that at least one out of five 
patients tested by NGS receives biomarker-driven 
treatment [7].
A major challenge to routine implementation in 
the care of patients with advanced NSCLC relates to 
tissue requirements for NGS. Our study did not evaluate 
the tissue requirements for NGS testing as part of a 
retrospective analysis because it was impossible to 
collect accurate data on the volume and cellularity of 
acquired specimens submitted for molecular analysis. 
At this time, comprehensive molecular analysis requires 
adequacy of tumor biopsy material. For histology 
specimens, for instance, FFPE samples stored as either 
tissue blocks or in unstained slides are required. A total 
tumor volume of > 1mm3 with > 80% cellularity (or 
> 30,000 cells) and tumor content (ratio of malignant 
to nonmalignant cells) of >20% are required for some 
targeted NGS assays [7]. However, approximately 
70% of lung cancer patients are diagnosed and staged 
using small biopsy specimens or cytology specimens 
[16]. It is unclear how many biopsies (transbronchial, 
endobronchial or transthoracic) are necessary to assure 
adequate amount for sample for testing. At the time of 
this writing, a 400-gene panel requires approximately 60 
ng of DNA while a 50-gene panel, approximately 10 ng 
of DNA. As one cell contains approximately 1 pg DNA, 
it results that the number of cells needed for current 
NGS panels varies between 10 and 60,000 cells. It is 
thus relevant for the proceduralist to acquire as much 
target tissue as safely possible and for the pathologist 
to minimize the number of immunostains (i.e. limit to 
P40/P63 and TTF-1), carefully review the specimens 
and quantify the cellularity prior to submission for NGS 
Oncotarget18881www.impactjournals.com/oncotarget
Table 2: Summary of the demographic characteristics of adenocarcinoma samples from EGFR, KRAS, and ALK 
tested specimens analyzed by FoundationOne, Caris Molecular Intelligence, and Response Genetics
Total EGFR EGFR



















































































(43) 39% (22) 57% (4) 56% (10)
13% 
(2) 0% (-) 0% (-) 0% (-)
100% 
(3) 0% (-) 0% (-) 100% (1)
29% 
(2)




(1) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-)
Other 1% (3) 1% (2) 2% (1) 0% (-) 0% (-) 7% (1) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-)





























































N = (289) (163) (84) (5) (34) (12) (13) (3) (3) (3) (3) (8)
Sex
Male 40% (116) 38% (62) 38% (32) 20% (1) 50% (17) 25% (3) 8% (1) 33% (1) 67% (2) 67% (2) 67% (2) 38% (3)
Female 60% (173)
62% 
(101) 62% (52) 80% (4) 50% (17) 75% (9) 92% (12) 67% (2) 33% (1) 33% (1) 33% (1) 63% (5)
Age
Mean (62.4) (62.4) (63.6) (77.1) (62.8) (65.5) (62.8) (72.2) (65.8) (68.4) (65.8) (59.9)
Race
White 65% (187) 60% (98) 69% (58) 80% (4) 65% (22) 75% (9) 69% 9 67% (2) 100% (3) 33% (1) 67% (2) 75% (6)
Black 25% (73) 26% (42) 27% (23) 20% (1) 32% (11) 25% (3) 23% (3) 33% (1) 0% (-) 67% (2) 0% (-) 25% (2)
Asian 8% (22) 11% (18) 2% (2) 0% (-) 3% (1) 0% (-) 8% (1) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-)
Other 1% (3) 1% (2) 1% (1) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 33% (1) 0% (-)































(109) 90% (76) 60% (3)
100% 




Smoker 27% (78) 33% (54) 10% (8) 40% (2) 0% (-) 8% (1) 31% (4) 0% (-) 0% (-) 0% (-) 0% (-) 13% (1)
Total ALK ALK














N = (289) (223) (23) (19) (1) (1) (1) (1)
Sex
Male 40% (116) 38% (84) 52% (12) 58% (11) 0% (-) 0% (-) 0% (-) 100% (1)
Female 60% (173) 62% (139) 48% (11) 37% (7) 100% (1) 100% (1) 100% (1) 0% (-)
Age
Mean (62.4) (63.5) (50.5) (48.8) (69.3) (47.8) (71.6) (63.8)
Race
White 65% (187) 61% (135) 87% (20) 79% (15) 100% (1) 100% (1) 100% (1) 100% (1)
Black 25% (73) 28% (63) 13% (3) 16% (3) 0% (-) 0% (-) 0% (-) 0% (-)
Asian 8% (22) 9% (20) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-)
Other 1% (3) 1% (2) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-)
Unknown 1% (3) 1% (2) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-) 0% (-)
Smoking
Smoker 73% (211) 76% (169) 39% (9) 26% (5) 100% (1) 100% (1) 0% (-) 100% (1)
Never Smoker 27% (78) 24% (54) 61% (14) 68% (13) 0% (-) 0% (-) 100% (1) 0% (-)
testing. Tissue requirement challenges may be soon 
overcome by blood-based assays. Circulating tumor 
cells and cell-free tumor DNA have shown promise for 
non-invasive genomic profiling to guide targeted therapy 
in NSCLC. Advancements in molecular technology 
including various isolation strategies and cell separation 
techniques could soon make it possible to routinely 
analyze clinically targetable genetic drivers in blood.
Based on current guideline recommendations [10, 
17, 18] patients should undergo diagnosis and staging 
in the same procedure. This is often achieved though 
endobronchial ultrasound-guided transbronchial needle 
aspiration (EBUS-TBNA) from mediastinal lymph 
nodes. It remains to be determined whether EBUS-
TBNA specimens (smears or cell blocks) are adequate for 
comprehensive NGS testing. NGS was shown, however, 
to be feasible in fine-needle aspiration biopsy (FNAB, 
FNA or NAB) cytology specimens from pulmonary and 
pancreatic lesions [19]. Molecular profiling of cytology 
samples has been shown to be reliable when compared 
with histological samples from the same patient [20, 21]. 
The use of smears for molecular testing is feasible and in 
fact could expedite care as smears can be reviewed as part 
of the rapid on site cytological examination (ROSE) at the 
time of the FNA (EBUS-, EUS- or CT-guided). Indeed, 
the addition of ROSE improves the adequacy of EBUS-
TBNA specimens for molecular profiling (EGFR, KRAS 
and ALK) and prevents the need for a repeat invasive 
diagnostic procedure aimed at molecular testing in at 
least 1 out of 10 patients [22]. To date, however, we don’t 
have enough evidence to show the relative success rates 
between core biopsies and needle aspirations techniques. 
In addition, core biopsies revealing tissue architecture 
may provide a better appreciation of the tumor-stroma and 
tumor- immune cells relationship, relevant for biomarker 
testing in immune-oncology. Whether this information 
can be obtained via needle techniques remains to be 
determined.
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There is a minimum number of genes required for 
testing in advanced NSCLC. In one study, the authors 
tested at least eleven genes for potential implication 
in adenocarcinoma [23] and demonstrated that in non-
smoking adenocarcinomas, there can be other alterations 
in a larger NGS panel. NGS identified targetable genomic 
alterations in 65% of tumors from patients with lung cancer 
who never smoked or were light smokers, whose tumors 
were deemed without targetable genomic alterations by 
earlier extensive non-NGS testing. These findings support 
first-line profiling of lung adenocarcinomas using an NGS 
approach as a more comprehensive and efficient strategy 
compared to non-NGS testing.
In conclusion, this study of targeted NGS in 
a group of patients with NSCLC cancer identified 
potentially targetable genetic alterations in the majority 
of patients across various tumor histology subtypes. 
NGS provides additional information by uncovering 
targetable concurrent alterations or alteration of unknown 
significance at this point in time, but potentially 
targetable in the future. The immediate consequences 
of NGS are relevant as genotype-directed treatment 
options for patients can be promptly implemented and 
enrollment in clinical trials can be expedited. NGS will 
likely continue to increase in importance as molecularly 
targeted therapeutic agents continue to show efficacy. 
The exact nature, quantity, and quality of specimens 
submitted for such comprehensive molecular analysis 
remains to be determined.
Figure 4: Genomic alteration in the entire cohort of adenocarcinoma samples. A. EGFR alteration. 23% of the EGFR tested 
samples showed genetic alteration. EGFR exon 19 deletion and gene amplification showed in majority of the samples. B. KRAS alteration. 
25% of KRAS tested samples showed genetic alteration and 40% of these KRAS alteration samples had G12C mutation. C. ALK alteration. 
9% of ALK tested samples showed genetic alteration and 83% of these ALK alteration samples had EML4-ALK rearrangements.
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MATERIALS AND METHODS
NSCLC samples and subjects
Patients suffering from advanced NSCLC (n=364), 
specifically adenocarcinoma (n=289), included in this 
analysis were evaluated at the University of Chicago 
Hospitals from December 2009 to August 2014 and 
underwent genotype testing at the discretion of the 
primary clinical provider. Patients were consented to 
Institutional Review Board (IRB) approved protocols 
9571 and 13473A or added under protocol 10-654N 
for deceased patients. This permitted the research team 
to access medical records for chart abstraction as well 
as analysis of results of clinical genetic testing for 
retrospective study. Tissue retrieved by core needle 
biopsies, excisional biopsies, or surgical resection 
could undergo NGS. Formalin-fixed paraffin-embedded 
(FFPE) samples stored as either tissue blocks or in 
unstained slides were procured by the testing facility. 
FoundationOne (Foundation Medicine, FM; Cambridge, 
MA), Caris Molecular Intelligence (CMI; Irving, TX), 
and Response Genetics Inc. (RG; Los Angeles, CA) 
were the companies that performed the genetic testing. 
Patients with genetic testing ordered from multiple 
companies done on the same specimen (n=3) had genetic 
results combined, utilizing the result from the company 
that performed the test. Patients with multiple biopsies 
sent for genetic testing were included as separate entries 
(n = 22).
Databases and study design
Retrospective review of Thoracic Oncology 
Research Program (TORP) Microsoft Access Databases 
provided patient demographics, pathology, and results 
of genetic testing. The TORP Access database has been 
previously described and validated [24–26]. Manual 
data abstraction from the patient files on electronic 
medical records (EPIC) was also performed for missing 
fields. The Cancer Registry database was utilized 
to obtain current vital status as well as date of death 
not recorded in Epic. Patients with a histologically 
confirmed diagnosis of NSCLC were included in this 
study if molecular testing was performed on their tumor. 
There were no restrictions of tumor histology, disease 
stage, subsequent or previous treatment or performance 
status. All the analyses were performed in Excel, with 
basic functions and formulas.
Genotype testing
The targeted NGS assays developed by 
FoundationOne from FM has been previously described 
and validated [27]. Samples sent to FM underwent 
whole-genome shotgun library construction with 
hybridization–based capture for 4,557 exons from 287 
cancer related genes and 47 introns from 19 genes 
frequently involved in DNA rearrangements. Samples 
sent to CMI underwent an established technology 
platforms to measure a panel of carefully selected 
biomarkers including immunohistochemistry (IHC), 
fluorescent in situ hybridization (FISH), polymerase 
chain reaction (PCR), and direct gene sequencing 
[28]. RG paired NGS with FISH and RNA expression 
markers to identify any clinically targetable genetic 
alteration in the samples. This technique has also been 
previously validated [29]. The reports were focused on 
FoundationOne NGS due to its complete panel of gene 
alteration testing in comparison with CMI and RG. 
Clinical testing for most genetic variants is performed 
in a CLIA-certified molecular genetics or molecular 
pathology laboratory. Our focus was on NGS, not on 
IHC or FISH, although we report the ALK FISH testing 
because of its accepted relevance to therapeutic decision 
making.
Statistical considerations
No formal statistical hypotheses were assessed. 
Statistical analyses were descriptive. The number of 
patients with genetic testing information determined the 
sample size. All descriptive analysis was performed using 
frequencies and percentiles.
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